Sign In
Buy IMRN
$1.15
+0.0900 (+8.49%)
At Close: Jun 22, 2026
Immuron Travelan® continued strong sales growth
06:00am, Friday, 17'th Jan 2025
Sales Highlights: Global December 2024 Quarter AUD$2.5 million up 70% on prior quarter, up 249% on pcp December 2024 Half Year AUD$4.0 million up 70% on pcp Australia December 2024 Quarter AUD$1.9 mil
Immuron Announces New Research Collaboration targeting Antimicrobial Resistance
06:00am, Wednesday, 15'th Jan 2025
Highlights: New Research Collaboration w ith Monash University One proposal will target Antimicrobial Resistant Pathways to develop broad spectrum therapeutic drug products Second project proposal wil
Immuron Announces Travelan® Clinical Trial Update
06:00am, Tuesday, 14'th Jan 2025
Highlights: Travelan® (IMM-124E) Phase 2 Clinical Study Report submitted to the FDA Travelan® (IMM-124E) Phase 2 Clinical Study Statistically Significant Immunology Results Travelan® (IMM-124E) Pha
Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th
06:00am, Monday, 02'nd Dec 2024
MELBOURNE, Australia, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the Small Cap
Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event
06:33pm, Thursday, 21'st Nov 2024
MELBOURNE, Australia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore presented early this morning at the
Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event
08:30am, Monday, 18'th Nov 2024
MELBOURNE, AUSTRALIA / ACCESSWIRE / November 18, 2024 / Immuron Limited (NASDAQ:IMRN) has one commercial product and two pipeline assets in three clinical programs for the treatment of gut mediated di
Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference
06:00am, Wednesday, 16'th Oct 2024
MELBOURNE, Australia, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be participating in a fireside
Immuron Travelan® continued strong sales growth
06:00am, Tuesday, 15'th Oct 2024
MELBOURNE, Australia, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study
06:30am, Friday, 04'th Oct 2024
MELBOURNE, Australia, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), is an Australian based and globally integrated biopharmaceutical company that has developed two commer
Traveler's Diarrhea Therapeutics Pipeline Market Report 2024 Featuring Immuron, Scandinavian Biopharma, and Sigmoid Pharma
09:42am, Thursday, 19'th Sep 2024
Dublin, Sept. 19, 2024 (GLOBE NEWSWIRE) -- The "Traveler's Diarrhea - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This "Traveler's Diarrhea - Pipeline
Immuron Plans Phase 2 Trial for IMM-529 following FDA review
11:54am, Thursday, 05'th Sep 2024
Key Points Immuron completes pre-IND meeting with FDA on the development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI) Previous clinical trial data on
Highlights: $3.5 (USD $2.3) million funding for NMRC and WRAIR approved by the U.S. Department of Defense to advance the development of Travelan. MELBOURNE, Australia, Aug. 16, 2024 (GLOBE NEWSWIRE) -
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference
06:14pm, Thursday, 15'th Aug 2024
MELBOURNE, Australia, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that our
Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect
06:00am, Wednesday, 07'th Aug 2024
MELBOURNE, Australia, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to invite shareholders to attend an investor webinar on MarketOpen Direct Connect to be held
Immuron requests pre-IND meeting for IMM-529 with FDA filing
06:00am, Tuesday, 02'nd Jul 2024
MELBOURNE, Australia, July 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce that it
